GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dermira Inc (NAS:DERM) » Definitions » Return-on-Tangible-Equity

Dermira (Dermira) Return-on-Tangible-Equity : -600.91% (As of Sep. 2019)


View and export this data going back to 2014. Start your Free Trial

What is Dermira Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Dermira's annualized net income for the quarter that ended in Sep. 2019 was $-230.48 Mil. Dermira's average shareholder tangible equity for the quarter that ended in Sep. 2019 was $38.36 Mil. Therefore, Dermira's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2019 was -600.91%.

The historical rank and industry rank for Dermira's Return-on-Tangible-Equity or its related term are showing as below:

DERM's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -48.465
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Dermira Return-on-Tangible-Equity Historical Data

The historical data trend for Dermira's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermira Return-on-Tangible-Equity Chart

Dermira Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Return-on-Tangible-Equity
Get a 7-Day Free Trial -66.97 -47.11 -41.53 -154.24 -323.44

Dermira Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -327.05 -1,389.71 -834.74 -105.06 -600.91

Competitive Comparison of Dermira's Return-on-Tangible-Equity

For the Biotechnology subindustry, Dermira's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermira's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dermira's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Dermira's Return-on-Tangible-Equity falls into.



Dermira Return-on-Tangible-Equity Calculation

Dermira's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2018 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2018 )  (A: Dec. 2017 )(A: Dec. 2018 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2018 )  (A: Dec. 2017 )(A: Dec. 2018 )
=-221.54/( (147.752+-10.762 )/ 2 )
=-221.54/68.495
=-323.44 %

Dermira's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2019 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Sep. 2019 )  (Q: Jun. 2019 )(Q: Sep. 2019 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Sep. 2019 )  (Q: Jun. 2019 )(Q: Sep. 2019 )
=-230.484/( (63.882+12.83)/ 2 )
=-230.484/38.356
=-600.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2019) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Dermira  (NAS:DERM) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Dermira Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Dermira's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermira (Dermira) Business Description

Industry
Traded in Other Exchanges
N/A
Address
275 Middlefield Road, Suite 150, Menlo Park, CA, USA, 94025
Dermira Inc is a biopharmaceutical company focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States.The company's late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne.
Executives
Halley E Gilbert director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
William R Ringo director
Fred B Craves director 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
David E Cohen director 3160 PORTER DRIVE, PALO ALTO CA 94304
Thomas G Wiggans director, officer: CEO & Chairman of the Board
Jason Raleigh Nunn director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Andrew Guggenhime officer: CFO C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Lori Lyons-williams officer: Chief Commercial Officer C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Kathleen Sebelius director C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Eugene A Bauer director, officer: Chief Medical Officer C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Lilly Eli & Co 10 percent owner LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285
Mark Mcdade director C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Matthew K Fust director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Canaan Partners Viii Llc director 285 RIVERSIDE AVE, STE 250, WESTPORT CT 06880
Canaan Viii Lp director 2765 SAND HILL RD, MENLO PARK CA 94025

Dermira (Dermira) Headlines

From GuruFocus